Literature DB >> 16550267

Introduction of leukotriene receptor antagonists in Manitoba.

C Macie1, K Wooldrage, J Manfreda, N R Anthonisen.   

Abstract

Patient characteristics and prescribing patterns during the introduction of leukotriene receptor antagonists (LTRA) in Manitoba are described using the provincial health database. Residents of Manitoba with asthma, chronic obstructive pulmonary disease, bronchitis or claims for respiratory medications were identified. Six thousand forty-one of 160,626 (3.8%) patients received LTRA; the likelihood of receiving LTRA increased if a patient was younger than 15 years, lived in a rural locale, had asthma, had frequent physician visits or used inhaled corticosteroids. Subsequent prescriptions (68%) were associated with the number of physician visits and inhaled corticosteroid use, which were thought to be indexes of severity. Patients, especially children, who received more than five prescriptions showed evidence of increased asthma control, but there was little evidence of benefit in less selected patient groups due, at least in part, to poor compliance with all respiratory drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16550267      PMCID: PMC2539010          DOI: 10.1155/2006/724167

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  21 in total

1.  Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma.

Authors:  D B Price; D Hernandez; P Magyar; J Fiterman; K M Beeh; I G James; S Konstantopoulos; R Rojas; J A van Noord; M Pons; L Gilles; J A Leff
Journal:  Thorax       Date:  2003-03       Impact factor: 9.139

Review 2.  Treatment of asthma with drugs modifying the leukotriene pathway.

Authors:  J M Drazen; E Israel; P M O'Byrne
Journal:  N Engl J Med       Date:  1999-01-21       Impact factor: 91.245

3.  Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma.

Authors:  M J Vaquerizo; P Casan; J Castillo; M Perpiña; J Sanchis; V Sobradillo; A Valencia; H Verea; J L Viejo; C Villasante; J Gonzalez-Esteban; C Picado
Journal:  Thorax       Date:  2003-03       Impact factor: 9.139

Review 4.  Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence.

Authors:  Francine M Ducharme
Journal:  BMJ       Date:  2003-03-22

5.  Leukotriene E4 and granulocytic infiltration into asthmatic airways.

Authors:  L A Laitinen; A Laitinen; T Haahtela; V Vilkka; B W Spur; T H Lee
Journal:  Lancet       Date:  1993-04-17       Impact factor: 79.321

6.  Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma.

Authors:  Owen J Dempsey; Stephen J Fowler; Andrew Wilson; Gwen Kennedy; Brian J Lipworth
Journal:  Chest       Date:  2002-07       Impact factor: 9.410

Review 7.  Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence.

Authors:  Francine M Ducharme
Journal:  BMJ       Date:  2002-06-29

8.  Leukotriene modifier use and asthma severity: how is a new medication being used by adults with asthma?

Authors:  Laurie Snyder; Paul D Blanc; Patricia P Katz; Edward H Yelin; Mark D Eisner
Journal:  Arch Intern Med       Date:  2004-03-22

9.  Comparison of patients' compliance with prescribed oral and inhaled asthma medications.

Authors:  J S Kelloway; R A Wyatt; S A Adlis
Journal:  Arch Intern Med       Date:  1994-06-27

Review 10.  Cysteinyl leukotrienes in asthma: old mediators up to new tricks.

Authors:  D W Hay; T J Torphy; B J Undem
Journal:  Trends Pharmacol Sci       Date:  1995-09       Impact factor: 14.819

View more
  1 in total

Review 1.  Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review.

Authors:  Tam Dang-Tan; Afisi Ismaila; Shiyuan Zhang; Victoria Zarotsky; Mark Bernauer
Journal:  BMC Res Notes       Date:  2015-09-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.